



Atty. Dkt. No. 076333-0331

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Robert H. Getzenberg  
Title: RENAL NUCLEAR MATRIX PROTEINS, POLYNUCLEOTIDE  
SEQUENCES ENCODING THEM, AND THEIR USE  
Appl. No.: 10/713,149  
Filing Date: 11/17/2003  
Examiner: Not yet assigned  
Art Unit: 2611

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Mail Stop PATENT APPLICATION  
Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application.

Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, *Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.*

Applicant submits herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. ; 09/850,128, filed ; 05/08/2001. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

**RELEVANCE OF EACH DOCUMENT**

All of the documents are in English.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date


5 March 2004

By

Stephen A. Bent

FOLEY & LARDNER LLP  
Customer Number: 23533  
Telephone: (202) 672-5404  
Facsimile: (202) 672-5399

Stephen A. Bent  
Attorney for Applicant  
Registration No. 29,768



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: March 8, 2004

(use as many sheets as necessary)

Sheet 1 of 4

**Complete if Known**

Application Number	10/713,149
Filing Date	11/17/2003
First Named Inventor	Robert H. GETZENBERG
Group Art Unit	2611
Examiner Name	Not yet assigned
Attorney Docket Number	076333-0331

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		4,882,268		Penman et al.	11/21/89	
		5,273,877		Fey et al.	12/28/93	
		5,849,509		Coffey et al.	12/15/98	
		5,866,535		Getzenberg et al.	2/2/99	
		4,885,236		Penman et al.	12/5/89	
		5,824,490		Coffey et al.	10/20/98	
		5,547,928		Wu et al.	08/20/96	
		6,232,443		Getzenberg	3/1998	
		5,989,826		Beausang et al.	11/23/1999	
		6,162,608		Beausang et al.	12/19/2000	
		6,410,247		Beausang et al.	6/25/2002	
		Re 35,747		Penman et al.	3/17/1998	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
		WO	95/16919			6/22/95		
		WO	93/09437			5/13/93		
		WO	94/00573			1/6/94		
		WO	87/03910			7/2/87		
		WO	94/18222			8/18/94		
		WO	97/16206			9/5/97		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		Miyana, N. et al., "Nuclear Matrix Proteins as a Urine Marker for Transitional Cell Carcinoma of the Bladder", The Journal of Urology Supplement, Vol. 153, No. 4 (XP-002068914)	
		Merrifield S. et al., "The Performance of the NMP22™ Test Kit: A Quantitative Enzyme Immuno-Assay for Bladder Cancer", Tumor Biology, 17 (suppl 1)(1996) (XP-002068915)	
		Getzenberg, R. et al., "Bladder Cancer-associated Nuclear Matrix Proteins", Cancer Research Vol. 56, No. 7, pp. 1690-1694, (1996). (XP-002068894).	
		Konety, B.R., Identification of Nuclear Matrix Protein Alterations Associated with Renal Cell Carcinoma", The Journal of Urology, Vol. 159, No. 4, pp. 1359-1363 (1998). (XP002068895).	

Examiner Signature


Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  Date Submitted: March 8, 2004  (use as many sheets as necessary)		<b>Complete if Known</b>	
		<b>Application Number</b>	10/713,149
Sheet 2 of 4		<b>Filing Date</b>	11/17/2003
		<b>First Named Inventor</b>	Robert H. GETZENBERG
		<b>Group Art Unit</b>	2611
		<b>Examiner Name</b>	Not yet assigned
		<b>Attorney Docket Number</b>	076333-0331

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		Eberhart A., et al., "Nuclear Matrix of the Lower Eukaryote Physarum Polycephalum and the mammalian epithelial LLC-PKI cell line—A comprehensive investigation of different preparation procedures", Vol. 212, No. 2, pp. 573-580 (1992). (XP02068893).	
		Keese, S.K., et al., "Utilization of Nuclear Matrix Proteins for Cancer Diagnosis", Critical Reviews in Eukaryotic Gene Expression", Vol., 6, No. 2&3, pp. 189-214 (1996). (XP002069158).	
		Getzenberg, R.H., "Nuclear Matrix and the Regulation of Gene Expression: Tissue Specificity", Journal of Cellular Biochemistry, Vol. 55, pp. 22-31 (1994).	
		Getzenberg, R.H. et al., "Identification of Nuclear Matrix Proteins in the Cancer and Normal Rat Prostate", Cancer Research, Vol. 51, pp. 6514-6520 (1994).	
		Berezney, R. et al., "Identification of a Nuclear Protein Matrix", Biochemical and Biophysical Research Communications, Vol. 60, No. 4 (1974).	
		Fey, E.G. et al., "The Nuclear Matrix: Defining Structural and Functional Roles", Eukaryotic Gene Expression, pp. 127-143 (1991).	
		Fey E.G. et al., "Tumor promoters induce a specific morphological signature in the nuclear matrix-intermediate filament scaffold of Madin-Darby canine kidney (MDCK) cell colonies", Proc. Natl. Acad. Sci. USA, vol. 81, pp. 4409-4413 (1984).	
		Fey E.G. et al., "Nuclear matrix proteins reflect cell type of origin in cultural human cells", Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 121-125 (1988).	
		Fey E.G. et al., "Epithelial Cytoskeletal Framework and Nuclear Matrix-Intermediate Filament Scaffold: Three-dimensional Organization and Protein Composition", The Journal of Cell Biology, Vol. 98, pp. 1973-1984 (1984).	
		Weidner, N. et al., "Rapid Communication, Localization of Nuclear Matrix Proteins (NMPs) in Multiple Tissue Types with NM-200.4™ (An Antibody Strongly Reactive with NMPs Found in Breast Carcinoma)", American Journal of Pathology, Vol. 138, No. 6, pp. 1293-1298 (1991).	
		Huse, W.D. et al., "Generation of a Large Combinatorial Library of the Immunoglobuline Repertoire in Phage Lambda", Research Article, pp. 1275-1281 (1989).	
		Mullinax, R.L. et al., "Identification of human antibody fragment clones specific for tetanus toxoid in a bacteriophage $\lambda$ immunoexpression library", Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 8095-8099 (1990).	
		Diener E. et al., Specific Immunosuppression by Immunotoxins Containing Daunomycin", Science Vol. 231, pp. 148-150 (1986).	
		Greiner, J.W., "Recombinant Interferon Enhances Monoclonal Antibody—Targeting of Carcinoma Lesions in Vivo", Reports, pp. 895-898 (1987).	
		Wolff B. et al., "The Use of Monoclonal Anti-Thy1IgG1 for the Targeting of Liposomes to AKR-A Cells in Vitro and In Vivo", Biochimica et Biophysica Acta, Vol. 802, pp. 259-273 (1984).	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: March 8, 2004  (use as many sheets as necessary)		<b>Application Number</b>	10/713,149		
		<b>Filing Date</b>	11/17/2003		
		<b>First Named Inventor</b>	Robert H. GETZENBERG		
		<b>Group Art Unit</b>	2611		
		<b>Examiner Name</b>	Not yet assigned		
<b>Sheet</b>	3	<b>of</b>	4	<b>Attorney Docket Number</b>	076333-0331

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		Weintraub H.M. "Antisense RNA and DNA" Scientific American pp. 40-46 (1990).	
		Cech, T.R. Ph.D., "Ribozymes and Their Medical Implications", JAMA, Vol. 260, No. 20, pp. 3030-3034 (1988).	
		Haseloff, J. et al. "Simple RNA enzymes with new and highly specific endoribonuclease activities" Nature, Vol. 334, pp. 585-591 (1988).	
		Bejany, D.E. et al., "Malignant Vesical Tumors Following Spinal Cord Injury", The Journal of Urology, Vol. 138, pp. 1390-1392 (1987).	
		Kaufman, J.M. et al. "Bladder Cancer and Squamous Metaplasia in Spinal Cord Injury Patients", pp. 967-971 (1977).	
		Melzak J. M.D., "The Incidence of Bladder Cancer in Paraplegia", Paraplegia, pp. 85-96.	
		Nyquist R.H., M.D. et al., "Mortality and Survival in Traumatic Myelof During Nineteen Years, from 1946 to 1965", Paraplegia, pp. 22-48.	
		El-Masri, W.S., "Bladder Cancer After Spinal Cord Injury", International Medical Society of Paraplegia, pp. 265-270 (1981).	
		Geisler, W.O., et al. "Survival in Traumatic Transverse Myelitis", Paraplegia, Vol. 14, pp. 262-275 (1977).	
		Hackler R.H., "A 25-Year Prospective Mortality Study In the Spinal Cord Injured Patient: Comparison With the Long-Term Living Paraplegic", The Journal of Urology, Vol. 117, pp. 486-488 (1977).	
		Pound, C.R. et al., "Differential Nuclear Matrix Protein (NMP) Patterns In Normal Renal Tissue and Renal Cell Carcinoma (RCC)", 92 <sup>nd</sup> Annual Meeting of the American Urological Association, New Orleans, LA, USA, (1997) J. of Urol. Vol. 157 (4 suppl.) (1997) (XP-002076374).	
		Konety B.R. et al., "Characteristic Nuclear Matrix Protein Alterations in Renal Cell Carcinoma (RCC)", 92 <sup>ND</sup> Annual Meeting of the American Urological Association, New Orleans, LA, USA (1997), J. or Urol., Vol. 157 (4 suppl.) (1997) (XP-002076375).	
		Gordon, J.N. et al., "Altered Extracellular Matrices Influence Cellular Processes and Nuclear Matrix Organizations of Overlying Human Bladder Urothelial Cells", Cancer Research, Vol. 53, pp. 4971-4977 (1993).	
		Cupo, J., "Electrophoretic analysis of nuclear matrix proteins and the potential clinical applications", Elsevier Science Publishers B.V., pp. 389-406 (1991).	
		Partin, A.W. et al., "Nuclear Matrix Protein Patterns in Human Benign Prostatic Hyperplasia and Prostate Cancer", Cancer Research, Vol. 53, pp. 744-746 (1993).	


<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: March 8, 2004

(use as many sheets as necessary)

Sheet 4 of 4

**Complete if Known**

Application Number	10/713,149
Filing Date	11/17/2003
First Named Inventor	Robert H. GETZENBERG
Group Art Unit	2611
Examiner Name	Not yet assigned
Attorney Docket Number	076333-0331

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		Russell, P.J. et al. "Preclinical studies of monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer", Cell biophysics, Vols. 24/25 pp. 155-61 (1994).	
		Kingsley E.A. et al., "Characterization of the anti-bladder-cancer monoclonal antibody BLCA -8: identification of its antigen as a neutral glycolipid", Cancer Immunology, Immunotherapy, Vol. 41, No. 6, pp. 348-54 (1995) (XP000872998).	
		Fradet Y., "Molecular and Immunologic approaches in the management of bladder cancer", Urologic Clinics of North America, Vol. 18. No. 3, pp. 515-24 (1991) (XP000881253).	
		Replogle-Schwab R. et al., "The utilization of nuclear matrix proteins for cancer diagnosis", Critical Reviews in Eukaryotic Gene Expression, Vol. 6, Nos. 2-3, pp. 103-13 (1996), (XP000881255).	
		Pirtskalaishvili G. et al., "Use of urine-based markers for detection and monitoring of bladder cancer", Techniques in Urology, Vol. 5, No. 4, pp. 179-84 (1999) (XP000881344).	
		J.E. Celis et al, "Expression of the transformation-sensitive protein "cyclin" in normal human epidermal basal cells and simian virus 40-transformed keratinocytes," Proc. Natl. Acad. Sci. USA, Vol. 81, pp. 3128-3132 (1984).	
		J.E. Celis et al., "Intermediate filaments in monkey kidney TC7 cells: Focal centers and interrelationship with other cytoskeletal systems", Proc. Natl. Acad. Sci. USA, Vol. 81, pp. 1117-1121 (1984).	
		R.G. DiScipio et al., "Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9", Proc. Natl. Acad. Sci. USA, vol. 81, pp. 7298-7302 (1984).	
		R.B. Merrifield, "Solid Phase Peptide Synthesis. I. The synthesis of a Tetrapeptide", J. Am. Chem. Soc., Vol. 85, No. 14, pp. 2149-2154 (1963).	
		Stewart and Young, "Solid Phase Peptide Synthesis" Freeman Publ. 1969, pp. 27-61.	
		J.Y. Douillard et al., "Monoclonal Antibodies Specific Immunotherapy of Gastrointestinal Tumors", Hybridoma, Vol. 5, Suppl. 1 (1986) pp. S139-S149.	
		Matritech, NMP22® Test Kit (6/96) pp. 1-39.	
		R. Fraley et al., "New Generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids", Trends Biochem. Sci., Vol. 6, pp. 77-80 (1981).	
		T. Gura, Science, "Systems for Identifying New Drugs Are Often Faulty", Nov. 1997, Vol. 278, pp. 1041-1042.	
		LH Hartwell et al., Science, "Integrating Genetic Approaches into the Discovery of Anticancer Drugs" Nov. 1997, Vol. 278, pp. 1064-1068.	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.